Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis

Bone Marrow Transplantation volume 46, pages 580–585 (2011)Cite this article

Subjects

Abstract

Acute GVHD (aGVHD) remains a major cause of mortality in patients undergoing allo-SCT. In particular, the outcome of those patients who fail first-line therapy with glucocorticosteroids is poor. Preliminary reports suggested that the purine analogue pentostatin might be effective for treatment of steroid-refractory aGVHD. Here, we report on our single-center experience with pentostatin in this condition. From 2005 to 2008, a total of 24 consecutive patients, who had undergone first-line salvage treatment for steroid-refractory aGVHD of the gastrointestinal tract with pentostatin, were identified from 301 patients allografted during that period and retrospectively analyzed. Response to treatment, defined as CR or very good PR (VGPR), was observed in nine patients (38%), with a median time to response of 10 days. Although pentostatin was associated with only moderate myelosuppressive toxicity, if any, 2-year survival was only 17% with five of the nine responders dying from infection (four patients) or recurrent GVHD (one patient). We conclude that pentostatin is a moderately effective therapy for steroid-refractory aGVHD, showing response and outcome rates similar to other clinically used regimens.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Van Lint MT, Milone G, Leotta S, Uderzo C, Scime R, Dallorso S et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006; 107: 4177–4181.

    Article  CAS  PubMed  Google Scholar 

  2. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008; 111: 2470–2475.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB . Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155–160.

    Article  PubMed  Google Scholar 

  4. Welniak LA, Blazar BR, Murphy WJ . Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25: 139–170.

    Article  CAS  PubMed  Google Scholar 

  5. Kolb HJ . Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112: 4371–4383.

    Article  CAS  PubMed  Google Scholar 

  6. Edinger M, Powrie F, Chakraverty R . Regulatory mechanisms in graft-versus-host responses. Biol Blood Marrow Transplant 2009; 15 (Suppl 1): 2–6.

    Article  PubMed  Google Scholar 

  7. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL . Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204–3213.

    CAS  PubMed  Google Scholar 

  8. Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M . Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ target. J Clin Invest 2000; 105: 1289–1298.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Luft T, Conzelmann M, Benner A, Rieger M, Hess M, Strohhaecker U et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood 2007; 110: 4535–4542.

    Article  CAS  PubMed  Google Scholar 

  10. He S, Cao Q, Qiu Y, Mi J, Zhang JZ, Jin M et al. A new approach to the blocking of alloreactive T-cell mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody. J Immunol 2008; 181: 7581–7592.

    Article  CAS  PubMed  Google Scholar 

  11. Spiers AS . Pentostatin (2prime prime or minute-deoxycoformycin): clinical pharmacology, role in cancer chemotherapy, and future prospects. Am J Ther 1995; 2: 196–216.

    Article  PubMed  Google Scholar 

  12. Resta R, Thompson LF . SCID: the role of adenosine deaminase deficiency. Immunol Today 1997; 19: 533–534.

    Google Scholar 

  13. Hershfield MS . New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 2005; 35: 31–41.

    Article  Google Scholar 

  14. Brown JB, Lee G, Grimm GR, Barrett TA . Therapeutic benefit of pentostatin in severe IL-10−/− colitis. Inflamm Bowel Dis 2008; 14: 880–887.

    Article  PubMed  Google Scholar 

  15. Döhner H, Ho AD, Thaler J, Stryckmans P, Sonneveld P, de Witte T et al. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J Natl Cancer Inst 1993; 85: 658–662.

    Article  PubMed  Google Scholar 

  16. Ho AD, Suciu S, Stryckmans P, De Cataldo F, Willemze R, Thaler J et al. Pentostatin in T-cell malignancies—a phase II trial of the EORTC. Leukemia Cooperative Group. Ann Oncol 1999; 10: 1493–1498.

    Article  CAS  PubMed  Google Scholar 

  17. Epstein J, Bealmear PM, Kennedy DW, Herrmann MJ, Islam A, Wiedl SC . Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pretreatment with 2′-deoxycoformycin. Exp Hematol 1986; 14: 845–849.

    CAS  PubMed  Google Scholar 

  18. Bolaños-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes G, Byrd JC et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005; 23: 2661–2668.

    Article  PubMed  Google Scholar 

  19. Klein S, Mousset S, Bug G, Wassmann B, Martin H . Long-Term follow up of a phase II study of pentostatin in patients with steroid refractory acute intestinal graft-versus-host disease. Bone Marrow Transplant 2008; 41 (Suppl 1): S222 (abstract 773).

    Google Scholar 

  20. Przepiorka JD, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  21. Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem HP et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009; 114: 702–708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP et al. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transplant 2009; 15: 777–784.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Knop S, Hebart H, Gscheidle H, Holler E, Kolb HJ, Niederwieser D et al. OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. Bone Marrow Transplant 2005; 36: 831–837.

    Article  CAS  PubMed  Google Scholar 

  24. Knop S, Hebart H, Gratwohl A, Kliem C, Faul C, Holler E et al. Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party. Leukemia 2009; 21: 1830–1833.

    Article  Google Scholar 

  25. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83–89.

    CAS  PubMed  Google Scholar 

  26. Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dörken B, Arnold R . Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 899–903.

    Article  CAS  PubMed  Google Scholar 

  27. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004; 104: 649–654.

    Article  CAS  PubMed  Google Scholar 

  28. Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, Perkins J et al. Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 1116–1121.

    Article  CAS  PubMed  Google Scholar 

  29. Perfetti P, Carlier P, Strada P, Gualandi F, Occhini D, Van Lint MT et al. Extracoporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008; 42: 609–617.

    Article  CAS  PubMed  Google Scholar 

  30. Greinix HT, Knobler RM, Worel N, Schneider B, Schneeberger A, Hoecker P et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006; 91: 405–408.

    PubMed  Google Scholar 

  31. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579–1586.

    Article  CAS  PubMed  Google Scholar 

  32. Von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009; 43: 245–251.

    Article  CAS  PubMed  Google Scholar 

  33. Martin PJ, Uberti JP, Soiffer RJ, Klingemann H, Waller EK, Daly AS et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant 2010; 16 (Suppl. 2): 169–170.

    Article  Google Scholar 

  34. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R et al. A biomarker panel for acute graft-versus-host disease. Blood 2009; 113: 273–278.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany

    T Schmitt, T Luft, U Hegenbart, A D Ho & P Dreger

  2. Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany

    T H Tran

Authors
  1. T Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Luft
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U Hegenbart
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T H Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A D Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Dreger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Schmitt.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmitt, T., Luft, T., Hegenbart, U. et al. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis. Bone Marrow Transplant 46, 580–585 (2011). https://doi.org/10.1038/bmt.2010.146

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.146

Keywords

This article is cited by

Search

Advanced search

Quick links